To help new drug research and development, Suzhou Industrial Park Kanglin Cancer Science and Technology Innovation Research Institute officially launched.

On September 25th, in order to promote the rapid development of clinical research and translational medicine research in China and accelerate the application of innovative drugs on oncology, the Kanglin Cancer Science and Technology Innovation Research Institute of Suzhou Industrial Park, a non-profit organization initiated by Professor Shen Lin, Vice President of Beijing Cancer Hospital, was officially launched with the active guidance and support of Suzhou Industrial Park.
IQVIA data analysis shows that in the second quarter of 2020, anti-tumor and immunomodulant classes were relatively less affected by the outbreak due to the expansion of the health insurance catalogue and the need for clinical drug use. Although the national investment in cancer drug research and development is very large, tumor drug development is also very smooth, but there is still a lot of room for improvement. According to the survey, the penetration rate of cancer treatment in China is only about 60%, which is far from meeting the demand. In addition, the professionals and resources required for the drug to enter clinical trials are scarce.
as a Jiangsu man and a clinical oncologist and researcher, Professor Shen Lin has been very concerned about the development of the biopharmaceutical industry in Suzhou, and has also seen some key bottlenecks in the development of innovative drugs. Against this background, with the strong support of the leadership of Suzhou Industrial Park, several oncology clinical researchers jointly initiated the establishment of the Kanglin Cancer Research Institute.
" Suzhou Biopharmaceutical Industry Cluster is a national strategic emerging industrial cluster, ranking first in the country. Professor Shen Lin said that Suzhou Industrial Park has an excellent environment for innovation and development, where they can make full use of their oncology clinical resources to work closely with Suzhou biomedical enterprises, medical institutions and research institutes, so as to promote the steady and rapid development of the biopharmaceutical industry, help health China's actions, benefit tens of millions of cancer patients, and reduce the economic burden on society.
Suzhou Industrial Park Kanglin Cancer Science and Technology Innovation Research Institute as a non-profit organization, the future will build a collaborative platform for preclinical research and development of new drugs and clinical transformation research, mainly committed to carrying out clinical-based chain research, to support the research and development and innovation of new drugs.
through the Research Institute, to promote the transformation of new drug research and development, promote clinical trials, accelerate drug approval, become China's clinical translation medicine national cancer research excellent collaborative platform and demonstration. At the same time, we will absorb and train a large number of clinical research and technical transformation talents, improve the level of clinical research and transformational research throughout the country, train the national clinical trial talents, and promote the development of the oncology drug industry. Finally accelerate the oncology innovation drugs, medical innovation technology landing, benefit tens of millions of cancer patients, benefit hundreds of millions of families, reduce the burden on society.
.